Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background. Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries. Methods. Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results. The severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups. Conclusion. Butylscopolamine20mgadministeredi.v. aftercomplainingCRBDduring recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.

Original languageEnglish
Pages (from-to)932-937
Number of pages6
JournalBritish Journal of Anaesthesia
Volume111
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Butylscopolammonium Bromide
Double-Blind Method
Urinary Bladder
Catheters
Placebos
Control Groups
Anesthesia
Analgesics
Urinary Catheterization
Muscarinic Antagonists
Postoperative Pain
Muscle Contraction
Catheterization
Pharmaceutical Preparations
Smooth Muscle
Maintenance
Safety
Pain

Keywords

  • Complications
  • Surgery
  • Urological

Cite this

@article{d07c21def1a34dc18873afe07dfe26e9,
title = "Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study",
abstract = "Background. Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries. Methods. Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results. The severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups. Conclusion. Butylscopolamine20mgadministeredi.v. aftercomplainingCRBDduring recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.",
keywords = "Complications, Surgery, Urological",
author = "Ryu, {Jung Hee} and Jung-Won Hwang and Lee, {J. W.} and Jeong-Hwa Seo and Park, {Hee Pyoung} and Oh, {Ah Young} and Jeon, {Young Tae} and Sanghwan Do",
year = "2013",
month = "12",
doi = "10.1093/bja/aet249",
language = "English",
volume = "111",
pages = "932--937",
journal = "British journal of anaesthesia",
issn = "0007-0912",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort

T2 - A prospective, randomized, placebo-controlled, double-blind study

AU - Ryu, Jung Hee

AU - Hwang, Jung-Won

AU - Lee, J. W.

AU - Seo, Jeong-Hwa

AU - Park, Hee Pyoung

AU - Oh, Ah Young

AU - Jeon, Young Tae

AU - Do, Sanghwan

PY - 2013/12

Y1 - 2013/12

N2 - Background. Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries. Methods. Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results. The severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups. Conclusion. Butylscopolamine20mgadministeredi.v. aftercomplainingCRBDduring recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.

AB - Background. Catheter-related bladder discomfort (CRBD) secondary to intraoperative catheterization of urinary bladder is one of the most distressing symptoms during recovery from anaesthesia. Butylscopolamine, a peripheral antimuscarinic agent, is effective for relieving the pain, which is because of smooth muscle contraction. The aim of this study was to assess the efficacy and safety profiles of butylscopolamine in treating CRBD after urological surgeries. Methods. Adult male patients undergoing urological surgery requiring urinary bladder catheterization intraoperatively were enrolled. Induction and maintenance of anaesthesia were standardized. Patients were randomized into two groups after complaining of CRBD in the post-anaesthesia care unit. The control group (n=29) received normal saline and the butylscopolamine group (n=28) was administered butylscopolamine 20 mg i.v. The severity of CRBD, postoperative pain, and adverse effects were assessed at baseline, 20 min, 1, 2, and 6 h after administration of the study drug. Results. The severity of CRBD observed in the butylscopolamine group was significantly lower than that of the control group at 1, 2, and 6 h after administration of the study drug [59 (12), 50 (16), 40 (21) in the control group vs 41 (22), 32 (25), 23 (18) in the butylscopolamine group, P<0.01]. Rescue analgesics were required less in the butylscopolamine group than in the control group (P=0.001). Adverse events were comparable between the two groups. Conclusion. Butylscopolamine20mgadministeredi.v. aftercomplainingCRBDduring recovery reduced both the severity of CRBD and the need for rescue analgesics without adverse effects in patients undergoing urologic surgeries.

KW - Complications

KW - Surgery

KW - Urological

UR - http://www.scopus.com/inward/record.url?scp=84887930713&partnerID=8YFLogxK

U2 - 10.1093/bja/aet249

DO - 10.1093/bja/aet249

M3 - Article

C2 - 23869107

AN - SCOPUS:84887930713

VL - 111

SP - 932

EP - 937

JO - British journal of anaesthesia

JF - British journal of anaesthesia

SN - 0007-0912

IS - 6

ER -